(3R,4S)-3-amino-1-(3-(2-(2,6-difluorophenyl)-quinazolin-8-ylamino)-pyridin-4-yl)piperidin-4-ol | 1214288-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: (3R,4S)-3-amino-1-(3-(2-(2,6-difluorophenyl)-quinazolin-8-ylamino)-pyridin-4-yl)piperidin-4-ol
• 英文别名: (3R,4S)-3-amino-1-[3-[[2-(2,6-difluorophenyl)quinazolin-8-yl]amino]pyridin-4-yl]piperidin-4-ol
• CAS: 1214288-13-7
• 化学式: C₂₄H₂₂F₂N₆O
• 分子量: 448.475
• InChiKey: WAISNUDWNYJNMT-UTKZUKDTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  100
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Heterocyclic Kinase Inhibitors
  申请人：Burger Matthew

  公开号：US20110195956A1

  公开（公告）日：2011-08-11

  New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

  提供了一种新的化合物、组合物和抑制与人类或动物宿主肿瘤发生相关的莫洛尼激酶（PIM激酶）活性的方法。在某些实施例中，该化合物和组合物有效抑制至少一种PIM激酶的活性。新的化合物和组合物可以单独使用，也可以与至少一种其他试剂联合使用，用于治疗由丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病，如癌症。
• HETEROCYCLIC PIM-KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2344473B1

  公开（公告）日：2014-04-16
• US8759338B2
  申请人：——

  公开号：US8759338B2

  公开（公告）日：2014-06-24
• [EN] HETEROCYCLIC PIM-KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE PIM
  申请人：NOVARTIS AG

  公开号：WO2010026122A1

  公开（公告）日：2010-03-11

  New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase- mediated disorder, such as cancer.